# US 2008/0293684 A1 · Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0293684 A1
- Document ID: US20080293684A1
- Status: Published application
- Kind: A1
- Application number: 11/658,546
- Filed: 2005-07-26
- Published: 2008-11-27
- Earliest claimed: 2004-07-30
- Inventors: Anthony B Pinkerton; Jean-Michel Vernier; Rowena V. Cube; John H. Hutchinson; Dehua Huang; Celine Bonnefous; Steven P. Govak; Theodore Kamenecka
- Web page: https://patentgrep.com/patent/US20080293684A1

## CPC

- C07D 311/16: substituted in position 7
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 45/71: being hydroxy groups
- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 69/734: Ethers
- C07C 69/92: with etherified hydroxyl groups
- C07C 217/76: having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C 217/92: the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
- C07C 235/42: having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C 255/54: containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
- C07C 323/12: the carbon skeleton being acyclic and saturated
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 213/30: Oxygen atoms
- C07D 213/53: Nitrogen atoms
- C07D 213/64: attached in position 2 or 6
- C07D 213/65: attached in position 3 or 5
- C07D 213/68: attached in position 4
- C07D 213/70: Sulfur atoms
- C07D 213/71: to which a second hetero atom is attached
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/84: Nitriles
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- C07D 215/20: Oxygen atoms
- C07D 217/02: with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 233/20: with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/60: with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 235/08: Radicals containing only hydrogen and carbon atoms
- C07D 235/10: Radicals substituted by halogen atoms or nitro radicals
- C07D 235/16: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 235/18: with aryl radicals directly attached in position 2
- C07D 239/34: One oxygen atom
- C07D 257/04: Five-membered rings
- C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 271/10: 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D 277/74: Sulfur atoms substituted by carbon atoms
- C07D 307/80: Radicals substituted by oxygen atoms
- C07D 311/22: with oxygen or sulfur atoms directly attached in position 4
- C07D 311/24: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D 473/38: attached in position 6
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

A compound of the formula I:
wherein:
A is selected from the group consisting of phenyl, napthyl, azetidinyl, benzoxazolyl, benzofuranyl, benzimidazolyl, chromenyl, dihydroindenyl, dihydroisoquinolinyl, isoquinolinyl, imidazolyl, imidazopyridinyl, indanyl, indazolyl, indolyl, oxadiazolyl, purinyl, pyridyl, pyrimidinyl, quinolinyl, tetrahydroisoquinolinyl, and tetrazolyl, which is unsubstituted or substituted with oxo;
X is selected from the group consisting of:
(1) a bond;
(2) —O—,
(3) —S—,
(4) —SO2—,
(5) —NH—,
(6) —N(C1-3alkyl)-,
(7) —O-phenyl-,
(8) —S-phenyl-,
(9) —S—C1-3 alkyl-phenyl-,
(10) -phenyl-, and
(11) -piperazinyl-;
Y is selected from the group consisting of:
(1) —O—,
(2) —NH(CO)—, and
(3) a bond;
R1 is selected from the group consisting of:
(1) hydrogen,
(2) C1-6alkyl, which is unsubstituted or substituted with a substituent selected from:
(a) halogen,
(b) hydroxyl, and
(c) phenyl, wherein the phenyl is unsubstituted or substituted with 1-5 substituents independently selected from halogen, cyano, CF3, hydroxyl, C1-6alkyl, and OC1-6alkyl,
(3) C3-7cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(4) phenyl, wherein the phenyl is unsubstituted or substituted with 1-5 substituents independently selected from halogen, hydroxyl, cyano, CF3, C1-6alkyl, and OC1-6alkyl, wherein the C1-6alkyl and OC1-6alkyl are linear or branched and optionally substituted with 1-5 halogen;
R2 is selected from the group consisting of:
(1) halogen,
(2) hydroxyl,
(3) —OC1-6alkyl, and
(4) C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl;
R3 is selected from the group consisting of:
(1) halogen, and
(2) C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl;
R4 may include multiple substituents and is independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C1-6alkyl, unsubstituted or substituted with halogen, —CN, —COC1-6alkyl or
—CO2C1-6alkyl,
(4) —O—C1-6alkyl,
(5) phenyl,
(6) pyridyl,
(7) thiazolyl,
(8) —CN, and
(9) hydroxyl,
or R4 may be joined to the phenyl ring at an adjacent carbon to form a dihydrofuranyl ring;
m is an integer selected from 0, 1, 2 and 3;
n is an integer selected from 0, 1, 2, 3, 4, 5 and 6;
or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 28)

The compound of claim 28 wherein A is phenyl.

### Claim 30 (depends on 28)

The compound of claim 28 wherein A is pyridyl.

### Claim 31 (depends on 28)

The compound of claim 28 wherein X is —O—.

### Claim 32 (depends on 28)

The compound of claim 28 wherein X is —S—.

### Claim 33 (depends on 32)

The compound of claim 32 wherein A is pyridyl and X is —S—.

### Claim 34 (depends on 28)

The compound of claim 28 wherein X is a bond and Y is —O—.

### Claim 35 (depends on 28)

The compound of claim 28 wherein X is —O-phenyl-.

### Claim 36 (depends on 28)

The compound of claim 28 wherein X is -phenyl-.

### Claim 37 (depends on 28)

The compound of claim 28 wherein R1 is C1-6alkyl.

### Claim 38 (depends on 37)

The compound of claim 37 wherein R1 is CH2CH(CH3)2.

### Claim 39 (depends on 28)

The compound of claim 28 wherein R2 is hydroxyl.

### Claim 40 (depends on 28)

The compound of claim 28 wherein R3 is methyl.

### Claim 41 (depends on 28)

The compound of claim 28 wherein R4 is hydrogen.

### Claim 42 (depends on 28)

The compound of claim 28 wherein m is 0.

### Claim 43 (depends on 28)

The compound of claim 28 wherein n is 1.

### Claim 44 (depends on 28)

The compound of claim 28 wherein n is 29.

### Claim 45

A compound which is selected from the group consisting of:
7-{4-[3-hydroxy-2-methyl-4-(3-methyl-butyryl)-phenoxy]-butoxy}-chromen-2-one;
1-[2-hydroxy-3-methyl-4-(4-phenoxy-butoxy)-phenyl]-3-methyl-butan-1-one;
1-[3-bromo-2-hydroxy-4-(4-phenoxy-butoxy)-phenyl]-3-methyl-butan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyridin-3-yloxy)-butoxy]-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyridin-2-yloxy)-butoxy]-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyridin-4-yloxy)-butoxy]-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-3-methyl-4-[3-(pyridin-3-yloxy)-propoxy]-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-4-[4-(2-methoxy-phenoxy)-butoxy]-3-methyl-phenyl}-3-methyl-butan-1-one;
7-{4-[2-bromo-3-hydroxy-4-(3-methyl-butyryl)-phenoxy]-butoxy}-chromen-2-one;
1-{3-bromo-2-hydroxy-4-[4-(pyridin-3-yloxy)-butoxy]-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-3-methyl 4-[5-(pyridin-3-yloxy)-pentyloxy]-phenyl}-3-methyl-butan-1-one;
1-{4-[4-(5-chloro-pyridin-3-yloxy)-butoxy]-2-hydroxy-3-methyl-phenyl}-3-methyl-butan-1-one;
1-{4-[4-(3-fluoro-phenoxy)-butoxy]-2-hydroxy-3-methyl-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(3-trifluoromethyl-phenoxy)-butoxy]-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-4-[4-(4-methoxy-phenoxy)-butoxy]-3-methyl-phenyl}-3-methyl-butan-1-one;
1-{4-[4-(3-chloro-phenoxy)-butoxy]-2-hydroxy-3-methyl-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyrimidin-2-yloxy)-butoxy]-phenyl}-3-methyl-butan-1-one;
1-{4-[4-(2-fluoro-phenoxy)-butoxy]-2-hydroxy-3-methyl-phenyl}-3-methyl-butan-1-one;
1-{4-[4-(2,3-difluoro-phenoxy)-butoxy]-2-hydroxy-3-methyl-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-4-[2-(isoquinolin-7-yloxy)-ethoxy]-3-methyl-phenyl}-3-methyl-butan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(naphthalen-2-yloxy)-butoxy]-phenyl}-3-methyl-butan-1-one;
1-{4-[4-(2,3-dihydro-1H-inden-5-yloxy)butoxy]-2-hydroxy-3-methylphenyl}-3-methylbutan-1-one;
6-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}indan-1-one;
1-(3-bromo-2-hydroxy-4-{[3-(pyridin-3-yloxy)benzyl]oxy}phenyl)-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(4-pyridin-4-ylpiperazin-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(4-pyridin-2-ylpiperazin-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-{4-[4-(3,4-dihydroisoquinolin-2(1H)-yl)butoxy]-2-hydroxy-3-methylphenyl}-3-methylbutan-1-one;
7-(3-{[2-bromo-3-hydroxy-4-(3-methylbutanoyl)phenoxy]methyl}phenoxy)-2H-chromen-2-one;
1-{3-bromo-4-[4-(2,3-difluorophenoxy)butoxy]-2-hydroxyphenyl}-3-methylbutan-1-one;
1-[2-hydroxy-3-methyl-4-(4-{methyl[(6-methylpyridin-2-yl)methyl]amino}butoxy)phenyl]-3-methylbutan-1-one;
7-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-4-methyl-2H-chromen-2-one;
7-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-4-(trifluoromethyl)-2H-chromen-2-one;
1-{2-hydroxy-3-methyl-4-[4-(2-pyridin-2-yl-1H-benzimidazol-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-4-[4-(1H-imidazo[4,5-b]pyridin-1-yl)butoxy]-3-methylphenyl}-3-methylbutan-1-one;
1-(4-{4-[(2-chloropyridin-3-yl)oxy]butoxy}-2-hydroxy-3-methylphenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{4-[(2-methylpyridin-3-yl)oxy]butoxy}phenyl)-3-methylbutan-1-one;
1-{4-[4-({2-[(dimethylamino)methyl]pyridin-3-yl}oxy)butoxy]-2-hydroxy-3-methylphenyl}-3-methylbutan-1-one;
6-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-4-methyl-2H-chromen-2-one;
7-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-3,4,8-trimethyl-2H-chromen-2-one;
1-(2-hydroxy-3-methyl-4-{4-[(6-methylpyridin-3-yl)oxy]butoxy}phenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{4-[4-(1,3,4-oxadiazol-2-yl)phenoxy]butoxy}phenyl)-3-methylbutan-1-one;
2,3-difluoro-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}benzonitrile;
1-{2-hydroxy-3-methyl-4-[4-(pentafluorophenoxy)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(2,3,5,6-tetrafluorophenoxy)butoxy]phenyl}-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{4-[(5-methylpyridin-3-yl)oxy]butoxy}phenyl)-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(2,3,4-trifluorophenoxy)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(2,3,6-trifluorophenoxy)butoxy]phenyl}-3-methylbutan-1-one;
1-(2-hydroxy-4-{4-[(2-iodopyridin-3-yl)oxy]butoxy}-3-methylphenyl)-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(5,6,7,8-tetrahydroquinolin-3-yloxy)butoxy]phenyl}-3-methylbutan-1-one;
7-{3-[2-bromo-3-hydroxy-4-(3-methylbutanoyl)phenoxy]propoxy}-2H-chromen-2-one;
1-{3-bromo-2-hydroxy-4-[4-(2-pyridin-2-yl-1H-benzimidazol-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-(4-{4-[(2,6-dimethylpyridin-3-yl)oxy]butoxy}-2-hydroxy-3-methylphenyl)-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyridin-4-ylthio)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-{4-[4-(2,3-dichlorophenoxy)butoxy]-2-hydroxy-3-methylphenyl}-3-methylbutan-1-one;
1-{3-bromo-2-hydroxy-4-[4-(5,6,7,8-tetrahydroquinolin-3-yloxy)butoxy]phenyl}-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-{4-[(2,3,5,6-tetrafluorophenyl)thio]butoxy}phenyl)-3-methylbutan-1-one;
1-(4-{4-[(5-bromopyridin-3-yl)oxy]butoxy}-2-hydroxy-3-methylphenyl)-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(3-pyridin-2-ylphenoxy)butoxy]phenyl}-3-methylbutan-1-one;
methyl-3-(2-hydroxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-phenyl)propanoate;
1-(2-hydroxy-3-methyl-4-{4-[2-(1,3-thiazol-4-yl)-1H-benzimidazol-1-yl]butoxy}phenyl)-3-methylbutan-1-one;
1-(4-{4-[(3-fluorophenyl)thio]butoxy}-2-hydroxy-3-methylphenyl)-3-methylbutan-1-one;
5-{3-[(4-Acetyl-3-hydroxy-2-propylphenoxy)methyl]phenoxy}pyridine-2-carbonitrile;
1-{2-hydroxy-3-methyl-4-[4-(4-pyridin-2-ylphenoxy)butoxy]phenyl}-3-methylbutan-1-one;
1-{4-[4-(1H-benzimidazol-1-yl)butoxy]-2-hydroxy-3-methylphenyl}-3-methylbutan-1-one;
(1-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butyl}-1H-benzimidazol-2-yl)acetonitrile;
1-(2-hydroxy-3-methyl-4-{4-[2-(trifluoromethyl)-1H-benzimidazol-1-yl]butoxy}phenyl)-3-methylbutan-1-one;
1-{3-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]benzyl}azetidine-3-carbonitrile;
1-{4-[4-(1,3-benzothiazol-2-ylthio)butoxy]-2-hydroxy-3-methylphenyl}-3-methylbutan-1-one;
1-(4-{4-[(6-chloro-1,3-benzoxazol-2-yl)thio]butoxy}-2-hydroxy-3-methylphenyl)-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(2-phenyl-1H-imidazol-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(2-phenyl-1H-benzimidazol-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{4-[(1-methyl-1H-tetrazol-5-yl)thio]butoxy}phenyl)-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(quinolin-3-yloxy)butoxy]phenyl}-3-methylbutan-1-one;
1-{4-[4-(1,3-benzoxazol-2-ylthio)butoxy]-2-hydroxy-3-methylphenyl}-3-methylbutan-1-one;
1-(4-{4-[(5-chloro-1,3-benzoxazol-2-yl)thio]butoxy}-2-hydroxy-3-methylphenyl)-3-methylbutan-1-one;
1-{2-hydroxy-4-[4-(1H-indol-1-yl)butoxy]-3-methylphenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(7H-purin-6-ylthio)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(2-phenyl-1H-indol-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyridin-4-ylsulfonyl)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyridin-3-ylthio)butoxy]phenyl}-3-methylbutan-1-one;
3′-[(4-Acetyl-3-hydroxy-2-propylphenoxy)methyl]biphenyl-2-carbonitrile;
1-hydroxy-3-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}pyridinium;
1-{2-hydroxy-3-methyl-4-[4-(4-methyl-2-phenyl-1H-imidazol-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{4-[2-(methylthio)-1H-benzimidazol-1-yl]butoxy}phenyl)-3-methylbutan-1-one;
1-(3-bromo-4-{4-[(6-chloro-1,3-benzoxazol-2-yl)thio]butoxy}-2-hydroxyphenyl)-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(4-phenyl-1H-imidazol-1-yl)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyridin-2-ylthio)butoxy]phenyl}-3-methylbutan-1-one;
1-(4-{4-[2-(2-chlorophenyl)-1H-benzimidazol-1-yl]butoxy}-2-hydroxy-3-methylphenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{4-[(1-oxidopyridin-2-yl)thio]butoxy}phenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[5-(2-phenyl-1H-benzimidazol-1-yl)pentyl]oxy}phenyl)-3-methylbutan-1-one;
7-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}chroman-2-one;
1-(2-hydroxy-3-methyl-4-{4-[4-(3-oxobutyl)phenoxy]butoxy}phenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[3-(pyridin-4-ylthio)benzyl]oxy}phenyl)-3-methylbutan-1-one;
1-[4-(4-{[2-(2-fluorophenyl)-1H-benzimidazol-1-yl]oxy}butoxy)-2-hydroxy-3-methylphenyl]-3-methylbutan-1-one;
1-[4-(4-{[2-(4-fluorophenyl)-1H-benzimidazol-1-yl]oxy}butoxy)-2-hydroxy-3-methylphenyl]-3-methylbutan-1-one;
1-(4-{4-[2-(2,4-dichlorophenyl)-1H-imidazol-1-yl]butoxy}-2-hydroxy-3-methylphenyl)-3-methylbutan-1-one;
1-[4-(4-{[2-(3-chlorophenyl)-1H-benzimidazol-1-yl]oxy}butoxy)-2-hydroxy-3-methylphenyl]-3-methylbutan-1-one;
7-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-2,3-dihydro-4H-chromen-4-one;
1-(2-hydroxy-4-{4-[4-(3-hydroxypropyl)phenoxy]butoxy}-3-methylphenyl)-3-methylbutan-1-one;
methyl 3-(4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)-propanoate;
1-{2-hydroxy-4-[2-(6-hydroxy-1-benzofuran-3-yl)ethoxy]-3-methylphenyl}-3-methylbutan-1-one;
methyl 2-hydroxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-benzoate;
ethyl 7-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}chromane-2-carboxylate;
1-{3-chloro-2,4-bis[4-(pyridin-4-ylthio)butoxy]phenyl}-3-methylbutan-1-one;
1-{3-bromo-2-hydroxy-4-[4-(pyridin-4-ylthio)butoxy]phenyl}-3-methylbutan-1-one;
1-{2-hydroxy-3-methyl-4-[4-(pyridin-4-ylthio)butoxy]phenyl}-3,3-dimethylbutan-1-one;
1-[2-hydroxy-3-methyl-4-({3-[(pyridin-4-ylthio)methyl]benzyl}oxy)phenyl]-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{4-[(2-phenyl-1H-benzimidazol-1-yl)oxy]butoxy}phenyl)-3,3-dimethylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[4-(pyridin-4-ylthio)benzyl]oxy}phenyl)-3-methylbutan-1-one;
1-{2-hydroxy-4-[4-(3-hydroxyphenoxy)butoxy]-3-methylphenyl}-3-methylbutan-1-one;
1-{4-[4-(3,4-dihydro-2H-chromen-7-yloxy)butoxy]-2-hydroxy-3-methylphenyl}-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[4-(pyridin-4-ylthio)benzyl]oxy}phenyl)-3,3-dimethylbutan-1-one;
1-(3-bromo-2-hydroxy-4-{[4-(pyridin-4-ylthio)benzyl]oxy}phenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[3-(pyridin-4-ylthio)benzyl]oxy}phenyl)-3,3-dimethylbutan-1-one;
3′-{[4-(3,3-dimethylbutanoyl)-3-hydroxy-2-methylphenoxy]methyl}biphenyl-3-carboxamide;
1-(3-bromo-2-hydroxy-4-{4-[(2-phenyl-1H-benzimidazol-1-yl)oxy]butoxy}phenyl)-3-methylbutan-1-one;
1-[2-hydroxy-3-methyl-4-({4-[(pyridin-4-ylthio)methyl]benzyl}oxy)phenyl]-3-methylbutan-1-one;
1-[2-hydroxy-4-({3-methoxy-4-[(pyridin-4-ylthio)methyl]benzyl}oxy)-3-methylphenyl]-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[2-(pyridin-4-ylthio)benzyl]oxy}phenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{4-[(2-methylpyridin-4-yl)thio]butoxy}phenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[3-(pyridin-3-ylamino)benzyl]oxy}phenyl)-3-methylbutan-1-one;
1-[2-hydroxy-3-methyl-4-({3-[(pyridin-4-ylthio)methyl]benzyl}oxy)phenyl]-3,3-dimethylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[3-(pyridin-2-ylamino)benzyl]oxy}phenyl)-3-methylbutan-1-one;
1-(2-hydroxy-3-methyl-4-{[3-(pyridin-4-ylamino)benzyl]oxy}phenyl)-3-methylbutan-1-one;
1-{2-hydroxy-4-[4-(1H-indazol-5-yloxy)butoxy]-3-methylphenyl}-3-methylbutan-1-one;
1-{2-hydroxy-4-[4-(1H-indazol-6-yloxy)butoxy]-3-methylphenyl}-3-methylbutan-1-one;
1-{2-hydroxy-4-[4-(1H-indol-4-yloxy)butoxy]-3-methylphenyl}-3-methylbutan-1-one;
1-{2-hydroxy-4-[4-(1H-indol-5-yloxy)butoxy]-3-methylphenyl}-3-methylbutan-1-one;
1-{2-hydroxy-4-[4-(1H-indol-6-yloxy)butoxy]-3-methylphenyl}-3-methylbutan-1-one;
ethyl 5-[(3-{[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]methyl}phenyl)amino]-2-methoxybenzoate;
1-[2-hydroxy-4-({3-[(3-methoxyphenyl)amino]benzyl}oxy)-3-methylphenyl]-3-methylbutan-1-one;
1-[4-({3-[(3-ethoxyphenyl)amino]benzyl}oxy)-2-hydroxy-3-methylphenyl]-3-methylbutan-1-one;
1-[2-hydroxy-4-({3-[(3-isopropylphenyl)amino]benzyl}oxy)-3-methylphenyl]-3-methylbutan-1-one;
1-[2-hydroxy-3-methyl-4-({3-[methyl(pyridin-2-yl)amino]benzyl}oxy)phenyl]-3-methylbutan-1-one;
1-{2-(benzyloxy)-3-methyl-4-[4-(pyridin-4-ylthio)butoxy]phenyl}-3-methylbutan-1-one;
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 28)

A pharmaceutical composition which comprises an inert carrier and a compound of claim 28 or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 28)

A method for potentiation of metabotropic glutamate receptor activity in a mammal which comprises the administration of an effective amount of the compound of claim 28 or a pharmaceutically acceptable salt thereof.

### Claim 48 (depends on 28)

A method for treating, controlling, ameliorating or reducing the risk of a neurological and psychiatric disorders associated with glutamate dysfunction in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of claim 28 or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 28)

A method for treating, controlling, ameliorating or reducing the risk of anxiety in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of claim 28 or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 28)

A method for treating, controlling, ameliorating or reducing the risk of depression in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of claim 28 or a pharmaceutically acceptable salt thereof.

### Claim 51 (depends on 28)

A method for treating, controlling, ameliorating or reducing the risk of schizophrenia in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of claim 28 or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 28)

A method for treating, controlling, ameliorating or reducing the risk of epilepsy in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of claim 28 or a pharmaceutically acceptable salt thereof.
